Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States

Weintraub, W. S., Bhatt, D. L., Zhang, Z., Dolman, S., Boden, W. E., Bress, A. P., Bellows, B. K., Derington, C. G., Philip, S., Steg, G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J., Ballantyne, C. M., & Kolm, P. (2024). Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States. Journal of the American Heart Association, 13(1). https://doi.org/10.1161/jaha.123.032413
Authors:
William S Weintraub
Deepak L Bhatt
Zugui Zhang
Sarahfaye Dolman
William E Boden
Adam P Bress
Brandon K Bellows
Catherine G Derington
Sephy Philip
Gabriel Steg
Michael Miller
Eliot A Brinton
Terry A Jacobson
Jean-Claude Tardif
Christie M Ballantyne
Paul Kolm
Affiliated Authors:
Brandon K Bellows
Subjects:
Author Keywords:
cardiovascular prevention
cost-effectiveness
hyperlipidemia
cost‐effectiveness
Publication Type:
Article
Unique ID:
10.1161/jaha.123.032413
PMID:
Publication Date:
Data Source:
PubMed

Record Created: